Abstract
The burden of hepatitis C (HCV) in the United States now exceeds that of HIV and hepatitis B combined. It is estimated that from 2010 to 2019, 193,000 HCV-related deaths, direct medical care costs of $10.7 billion, and $75.3 billion in societal costs can be expected. HCV-associated liver related morbidity and mortality is an important component of this burden [Wong JB et al. Am J Public Health 2000]. This article discusses how antiviral therapy targeted to achieve viral eradication is the key strategy to stabilizing or reversing liver injury and fibrosis, and reducing the risk of liver-related complications, including cirrhosis and liver cancer, in patients with HCV.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
